<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02097277</url>
  </required_header>
  <id_info>
    <org_study_id>MB130-002</org_study_id>
    <nct_id>NCT02097277</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Effects of BMS-986036 in Obese Adults With Type-2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the potential of BMS-986036 for treatment obese adults
      with type-2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 15, 2014</start_date>
  <completion_date type="Actual">May 17, 2016</completion_date>
  <primary_completion_date type="Actual">September 22, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Week 12</measure>
    <time_frame>Baseline (Day 1) and Week 12</time_frame>
    <description>HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Percent Change in Glycosylated Hemoglobin A1c (HbA1c) from Baseline to Week 12 was reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight From Baseline to Week 12</measure>
    <time_frame>Baseline (Day 1) and Week 12</time_frame>
    <description>Change in Body Weight from Baseline to Week 12 as a part of Physical measurement was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in Insulin Sensitivity Quantified by Composite Index of Insulin Sensitivity (CISI) (Matsuda Index)</measure>
    <time_frame>Baseline (Day 1) and Week 12</time_frame>
    <description>Whole body insulin sensitivity as quantified by Matsuda Index at the end of the treatment period, calculated by the following equation: 10,000/square root of(FPG*FI)*(FPG+PG30*2+PG60*3+PG120*2)/8*(FPI+PI30*2+PI60*3+PI120*2)/8). FPG=fasting plasma glucose level; FPI=fasting plasma insulin level; PG30,60,90, and 120=plasma glucose levels sampled at 30,60, and 120 minutes after oral glucose load; PI30,60,and 120=plasma insulin levels sampled at 30,60 and 120 minutes after the oral glucose load.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in Insulin Sensitivity Quantified by Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)</measure>
    <time_frame>Baseline (Day 1) and Week 12</time_frame>
    <description>Homeostasis model assessment of insulin resistance (HOMA-IR) was used as a validated measure of insulin resistance. HOMA-IR is calculated using the following formula's fasting glucose(mg/dL) x fasting insulin(mU/L) / 405.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in Insulin Sensitivity Quantified by Quantitative Insulin Sensitivity Check Index (QUICKI)</measure>
    <time_frame>Baseline (Day 1) and Week 12</time_frame>
    <description>The Quantitative Insulin Sensitivity Check Index (QUICKI) score, measures insulin sensitivity which is the inverse of insulin resistance. QUICKI is derived using the inverse of the sum of the logarithms of the fasting insulin and fasting glucose: 1 / (log(fasting insulin mU/L) + log(fasting glucose mg/dL)).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Oral Glucose Tolerance Test (OGTT) Area Under the Curve From 0 to 2 Hours for Postprandial Glucose From Baseline to Week 12</measure>
    <time_frame>Baseline (Day 1) and Week 12</time_frame>
    <description>Blood samples were drawn after an overnight fast and standard OGTT from 0 to 120 minutes. Plasma Glucose levels over 2 hours were shown as Area Under the Curve, (AUC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in OGTT Insulin AUC (0-2 Hours) From Baseline to Week 12</measure>
    <time_frame>Bseline (Day 1) and Week 12</time_frame>
    <description>Blood samples were drawn after an overnight fast and standard OGTT from 0 to 120 minutes. Insulin levels over 2 hours were shown as Area Under the Curve, (AUC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in OGTT C-peptide AUC (0-2 Hours) From Baseline to Week 12</measure>
    <time_frame>Baseline (Day 1) and Week 12</time_frame>
    <description>Blood samples were drawn after an overnight fast and standard OGTT from 0 to 120 minutes. C-peptide levels over 2 hours were shown as Area Under the Curve, (AUC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Concentration (Cavg) of C-terminal Intact BMS-986036</measure>
    <time_frame>Pre-dose, 6, 24 hours postdose on Week 8; pre-dose on Weeks 1, 2, 4, 6, 8, and 12; post treatment period on Week 13, 15 and 18 (Day 126)</time_frame>
    <description>Cavg of C-terminal Intact BMS-986036 was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) of C-terminal Intact BMS-986036</measure>
    <time_frame>Pre-dose, 6, 24 hours postdose on Week 8; pre-dose on Weeks 1, 2, 4, 6, 8, and 12; post treatment period on Week 13, 15 and 18 (Day 126)</time_frame>
    <description>Maximum observed concentration (Cmax) of C-terminal Intact BMS-986036 was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve From Time Zero to 24 Hours at Steady State (AUC [0-24 Hours, ss]) of C-terminal Intact BMS-986036</measure>
    <time_frame>Pre-dose, 6, 24 hours postdose on Week 8</time_frame>
    <description>AUC [0-24 hours, ss] of C-terminal Intact BMS-986036 was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve From Time Zero to 168 Hours at Steady State (AUC [0-168 Hours, ss]) of C-terminal Intact BMS-986036</measure>
    <time_frame>Pre-dose, 6, 24 hours postdose on Week 8; pre-dose on Weeks 1, 2, 4, 6, 8, and 12; post treatment period on Week 13, 15 and 18 (Day 126)</time_frame>
    <description>AUC [0-168 hours, ss] of C-terminal Intact BMS-986036 was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Concentration (Cavg) of Total BMS-986036</measure>
    <time_frame>Pre-dose, 6, 24 hours postdose on Week 8; pre-dose on Weeks 1, 2, 4, 6, 8, and 12; post treatment period on Week 13, 15 and 18 (Day 126)</time_frame>
    <description>Cavg of Total BMS-986036 was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) of Total BMS-986036</measure>
    <time_frame>Pre-dose, 6, 24 hours postdose on Week 8; pre-dose on Weeks 1, 2, 4, 6, 8, and 12; post treatment period on Week 13, 15 and 18 (Day 126)</time_frame>
    <description>Maximum observed concentration (Cmax) of Total BMS-986036 was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve From Time Zero to 24 Hours at Steady State (AUC [0-24 Hours, ss]) Total BMS-986036</measure>
    <time_frame>Pre-dose, 6, 24 hours postdose on Week 8</time_frame>
    <description>AUC [0-24 hours, ss] of Total BMS-986036 was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve From Time Zero to 168 Hours at Steady State (AUC [0-168 Hours, ss]) of Total BMS-986036</measure>
    <time_frame>Pre-dose, 6, 24 hours postdose on Week 8; pre-dose on Weeks 1, 2, 4, 6, 8, and 12; post treatment period on Week 13, 15 and 18 (Day 126)</time_frame>
    <description>AUC [0-168 hours, ss] of Total BMS- 986036 was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ANTI-BMS-986036 Antibody Response</measure>
    <time_frame>Baseline and Day 126</time_frame>
    <description>Percentage of Participants with ANTI-BMS-986036 Antibody Response (ADA positive and ADA Negative) was reported. Participants were monitored for antibodies to BMS-986036 with an anti-BMS-986036 antibody assay. Titers were reported for samples testing positive in an assay.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">219</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <arm_group>
    <arm_group_label>Treatment A: Placebo (Matching with BMS-986036 - Daily)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (Matching with BMS-986036) 0 mg subcutaneous injection once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Treatment B: BMS-986036 (1 mg Daily)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986036 1 mg subcutaneous injection once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C: BMS-986036 (5 mg Daily)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986036 5 mg subcutaneous injection once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D: BMS-986036 (20 mg Daily)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986036 20 mg subcutaneous injection once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment E: BMS-986036 (20 mg Weekly)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986036 20 mg subcutaneous injection once weekly (on Day 1 of each week) for 12 weeks
Followed by Placebo (Matching with BMS-986036) 0 mg subcutaneous injection on Days 2-7 of each week for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BMS-986036</intervention_name>
    <arm_group_label>Arm 2: Treatment B: BMS-986036 (1 mg Daily)</arm_group_label>
    <arm_group_label>Treatment C: BMS-986036 (5 mg Daily)</arm_group_label>
    <arm_group_label>Treatment D: BMS-986036 (20 mg Daily)</arm_group_label>
    <arm_group_label>Treatment E: BMS-986036 (20 mg Weekly)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo (Matching with BMS-986036)</intervention_name>
    <arm_group_label>Treatment A: Placebo (Matching with BMS-986036 - Daily)</arm_group_label>
    <arm_group_label>Treatment E: BMS-986036 (20 mg Weekly)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Diagnosed with type-2 diabetes mellitus with HbA1c ≥6.5% to less than 10.0%

          -  Body mass index 30.0 to 50.0

        Exclusion Criteria:

          -  Any significant acute or chronic medical illness

          -  Inability to self-administer subcutaneous injections

          -  Inability to be venipunctured

          -  Evidence of organ dysfunction beyond what is consistent with the target population

          -  History of allergy to PEGylated compounds or Fibroblast growth factor 21 (FGF21)
             related compounds
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arkansas Clinical Research</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anaheim Clinical Trials Llc</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Encompass Clinical Research</name>
      <address>
        <city>Spring Valley</city>
        <state>California</state>
        <zip>91978-1522</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Encompass Clinical Research</name>
      <address>
        <city>Spring Valley</city>
        <state>California</state>
        <zip>91978</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>All Medical Research, Llc</name>
      <address>
        <city>Cooper City</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Kentucky Research Associates, Inc.</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Research</name>
      <address>
        <city>Trenton</city>
        <state>New Jersey</state>
        <zip>08611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metrolina Internal Medicine</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sterling Research Grp, Ltd.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manna Research Vancouver</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6J 1S3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aggarwal And Associates</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6T 0G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhodin Recherche Clinique</name>
      <address>
        <city>Drummondville</city>
        <state>Quebec</state>
        <zip>J2B 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Recherche Gcp Research</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1M 1B1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medexa Recherche</name>
      <address>
        <city>Victoriaville</city>
        <state>Quebec</state>
        <zip>G6P 6P6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alpha-Recherche Clinique</name>
      <address>
        <city>Quebec</city>
        <zip>G3K 2P8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>March 19, 2014</study_first_submitted>
  <study_first_submitted_qc>March 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2014</study_first_posted>
  <results_first_submitted>March 14, 2019</results_first_submitted>
  <results_first_submitted_qc>April 16, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 9, 2019</results_first_posted>
  <disposition_first_submitted>March 22, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>March 22, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 24, 2017</disposition_first_posted>
  <last_update_submitted>July 29, 2019</last_update_submitted>
  <last_update_submitted_qc>July 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>219 participants were enrolled; 138 entered the lead-in period. Reasons for not entering lead-in period included “not meeting study eligibility criteria”. 120 were randomized to treatment. Reasons not randomized: 6 withdrew consent, 2 lost to follow-up, 4 no longer met study criteria, 1 due to admin.reason by Sponsor and 4 due to other reasons.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment A: Placebo</title>
          <description>Placebo (Matching with BMS-986036) 0 mg subcutaneous injection once daily for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Treatment B: BMS-986036 (1 mg Daily)</title>
          <description>BMS-986036 1 mg subcutaneous injection once daily for 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Treatment C: BMS-986036 (5 mg Daily)</title>
          <description>BMS-986036 5 mg subcutaneous injection once daily for 12 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Treatment D: BMS-986036 (20 mg Daily)</title>
          <description>BMS-986036 20 mg subcutaneous injection once daily for 12 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Treatment E: BMS-986036 (20 mg Weekly)</title>
          <description>BMS-986036 20 mg subcutaneous injection once weekly (on Day 1 of each week) for 12 weeks followed by Placebo (Matching with BMS-986036) 0 mg subcutaneous injection on Days 2-7 of each week for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="24"/>
                <participants group_id="P5" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subject no longer meets study criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject request to discontinue treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment A: Placebo</title>
          <description>Placebo (Matching with BMS-986036) 0 mg subcutaneous injection once daily for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Treatment B: BMS-986036 (1 mg Daily)</title>
          <description>BMS-986036 1 mg subcutaneous injection once daily for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Treatment C: BMS-986036 (5 mg Daily)</title>
          <description>BMS-986036 5 mg subcutaneous injection once daily for 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Treatment D: BMS-986036 (20 mg Daily)</title>
          <description>BMS-986036 20 mg subcutaneous injection once daily for 12 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Treatment E: BMS-986036 (20 mg Weekly)</title>
          <description>BMS-986036 20 mg subcutaneous injection once weekly (on Day 1 of each week) for 12 weeks followed by Placebo (Matching with BMS-986036) 0 mg subcutaneous injection on Days 2-7 of each week for 12 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="24"/>
            <count group_id="B4" value="24"/>
            <count group_id="B5" value="24"/>
            <count group_id="B6" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.9" spread="7.58"/>
                    <measurement group_id="B2" value="55.4" spread="9.44"/>
                    <measurement group_id="B3" value="55.3" spread="9.92"/>
                    <measurement group_id="B4" value="56.2" spread="8.17"/>
                    <measurement group_id="B5" value="55.2" spread="12.62"/>
                    <measurement group_id="B6" value="56.0" spread="9.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="95"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Week 12</title>
        <description>HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Percent Change in Glycosylated Hemoglobin A1c (HbA1c) from Baseline to Week 12 was reported.</description>
        <time_frame>Baseline (Day 1) and Week 12</time_frame>
        <population>The Pharmacodynamic Population included all subjects who received at least one dose of study medication and had PD biomarker data available, although only participants with both baseline and post-baseline data were included in the statistical analysis. Here, 'N' signifies number of participants analyzed for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: Placebo</title>
            <description>Placebo (Matching with BMS-986036) 0 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: BMS-986036 (1 mg Daily)</title>
            <description>BMS-986036 1 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: BMS-986036 (5 mg Daily)</title>
            <description>BMS-986036 5 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: BMS-986036 (20 mg Daily)</title>
            <description>BMS-986036 20 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Treatment E: BMS-986036 (20 mg Weekly)</title>
            <description>BMS-986036 20 mg subcutaneous injection once weekly (on Day 1 of each week) for 12 weeks followed by Placebo (Matching with BMS-986036) 0 mg subcutaneous injection on Days 2-7 of each week for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Week 12</title>
          <description>HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Percent Change in Glycosylated Hemoglobin A1c (HbA1c) from Baseline to Week 12 was reported.</description>
          <population>The Pharmacodynamic Population included all subjects who received at least one dose of study medication and had PD biomarker data available, although only participants with both baseline and post-baseline data were included in the statistical analysis. Here, 'N' signifies number of participants analyzed for this outcome measure.</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0005" spread="0.00622"/>
                    <measurement group_id="O2" value="0.0029" spread="0.00882"/>
                    <measurement group_id="O3" value="0.0007" spread="0.00692"/>
                    <measurement group_id="O4" value="0.0004" spread="0.00814"/>
                    <measurement group_id="O5" value="-0.0004" spread="0.00418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Weight From Baseline to Week 12</title>
        <description>Change in Body Weight from Baseline to Week 12 as a part of Physical measurement was reported.</description>
        <time_frame>Baseline (Day 1) and Week 12</time_frame>
        <population>The Pharmacodynamic Population included all subjects who received at least one dose of study medication and had PD biomarker data available, although only subjects with both baseline and post-baseline data were included in the statistical analysis. Here, 'N' signifies number of participants analyzed for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: Placebo</title>
            <description>Placebo (Matching with BMS-986036) 0 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: BMS-986036 (1 mg Daily)</title>
            <description>BMS-986036 1 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: BMS-986036 (5 mg Daily)</title>
            <description>BMS-986036 5 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: BMS-986036 (20 mg Daily)</title>
            <description>BMS-986036 20 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Treatment E: BMS-986036 (20 mg Weekly)</title>
            <description>BMS-986036 20 mg subcutaneous injection once weekly (on Day 1 of each week) for 12 weeks followed by Placebo (Matching with BMS-986036) 0 mg subcutaneous injection on Days 2-7 of each week for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Weight From Baseline to Week 12</title>
          <description>Change in Body Weight from Baseline to Week 12 as a part of Physical measurement was reported.</description>
          <population>The Pharmacodynamic Population included all subjects who received at least one dose of study medication and had PD biomarker data available, although only subjects with both baseline and post-baseline data were included in the statistical analysis. Here, 'N' signifies number of participants analyzed for this outcome measure.</population>
          <units>Kilogram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" spread="2.615"/>
                    <measurement group_id="O2" value="-0.26" spread="1.718"/>
                    <measurement group_id="O3" value="-0.10" spread="2.883"/>
                    <measurement group_id="O4" value="-1.09" spread="2.583"/>
                    <measurement group_id="O5" value="-0.50" spread="2.297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in Insulin Sensitivity Quantified by Composite Index of Insulin Sensitivity (CISI) (Matsuda Index)</title>
        <description>Whole body insulin sensitivity as quantified by Matsuda Index at the end of the treatment period, calculated by the following equation: 10,000/square root of(FPG*FI)*(FPG+PG30*2+PG60*3+PG120*2)/8*(FPI+PI30*2+PI60*3+PI120*2)/8). FPG=fasting plasma glucose level; FPI=fasting plasma insulin level; PG30,60,90, and 120=plasma glucose levels sampled at 30,60, and 120 minutes after oral glucose load; PI30,60,and 120=plasma insulin levels sampled at 30,60 and 120 minutes after the oral glucose load.</description>
        <time_frame>Baseline (Day 1) and Week 12</time_frame>
        <population>The Pharmacodynamic Population included all participants who received at least one dose of study medication and had PD biomarker data available, although only participants with both baseline and post-baseline data were included in the statistical analysis. Here, 'N' signifies number of participants analyzed for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: Placebo</title>
            <description>Placebo (Matching with BMS-986036) 0 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: BMS-986036 (1 mg Daily)</title>
            <description>BMS-986036 1 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: BMS-986036 (5 mg Daily)</title>
            <description>BMS-986036 5 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: BMS-986036 (20 mg Daily)</title>
            <description>BMS-986036 20 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Treatment E: BMS-986036 (20 mg Weekly)</title>
            <description>BMS-986036 20 mg subcutaneous injection once weekly (on Day 1 of each week) for 12 weeks followed by Placebo (Matching with BMS-986036) 0 mg subcutaneous injection on Days 2-7 of each week for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Insulin Sensitivity Quantified by Composite Index of Insulin Sensitivity (CISI) (Matsuda Index)</title>
          <description>Whole body insulin sensitivity as quantified by Matsuda Index at the end of the treatment period, calculated by the following equation: 10,000/square root of(FPG*FI)*(FPG+PG30*2+PG60*3+PG120*2)/8*(FPI+PI30*2+PI60*3+PI120*2)/8). FPG=fasting plasma glucose level; FPI=fasting plasma insulin level; PG30,60,90, and 120=plasma glucose levels sampled at 30,60, and 120 minutes after oral glucose load; PI30,60,and 120=plasma insulin levels sampled at 30,60 and 120 minutes after the oral glucose load.</description>
          <population>The Pharmacodynamic Population included all participants who received at least one dose of study medication and had PD biomarker data available, although only participants with both baseline and post-baseline data were included in the statistical analysis. Here, 'N' signifies number of participants analyzed for this outcome measure.</population>
          <units>Unit on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" spread="0.967"/>
                    <measurement group_id="O2" value="-0.19" spread="1.348"/>
                    <measurement group_id="O3" value="-0.18" spread="2.102"/>
                    <measurement group_id="O4" value="0.77" spread="2.455"/>
                    <measurement group_id="O5" value="0.54" spread="1.772"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in Insulin Sensitivity Quantified by Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)</title>
        <description>Homeostasis model assessment of insulin resistance (HOMA-IR) was used as a validated measure of insulin resistance. HOMA-IR is calculated using the following formula's fasting glucose(mg/dL) x fasting insulin(mU/L) / 405.</description>
        <time_frame>Baseline (Day 1) and Week 12</time_frame>
        <population>The Pharmacodynamic Population included all participants who received at least one dose of study medication and had PD biomarker data available, although only participants with both baseline and post-baseline data were included in the statistical analysis. Here, 'N' signifies number of participants analyzed for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: Placebo</title>
            <description>Placebo (Matching with BMS-986036) 0 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: BMS-986036 (1 mg Daily)</title>
            <description>BMS-986036 1 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: BMS-986036 (5 mg Daily)</title>
            <description>BMS-986036 5 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: BMS-986036 (20 mg Daily)</title>
            <description>BMS-986036 20 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Treatment E: BMS-986036 (20 mg Weekly)</title>
            <description>BMS-986036 20 mg subcutaneous injection once weekly (on Day 1 of each week) for 12 weeks followed by Placebo (Matching with BMS-986036) 0 mg subcutaneous injection on Days 2-7 of each week for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Insulin Sensitivity Quantified by Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)</title>
          <description>Homeostasis model assessment of insulin resistance (HOMA-IR) was used as a validated measure of insulin resistance. HOMA-IR is calculated using the following formula's fasting glucose(mg/dL) x fasting insulin(mU/L) / 405.</description>
          <population>The Pharmacodynamic Population included all participants who received at least one dose of study medication and had PD biomarker data available, although only participants with both baseline and post-baseline data were included in the statistical analysis. Here, 'N' signifies number of participants analyzed for this outcome measure.</population>
          <units>Unit on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="4.136"/>
                    <measurement group_id="O2" value="0.00" spread="5.633"/>
                    <measurement group_id="O3" value="-1.88" spread="8.940"/>
                    <measurement group_id="O4" value="-1.73" spread="4.589"/>
                    <measurement group_id="O5" value="-0.34" spread="3.707"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in Insulin Sensitivity Quantified by Quantitative Insulin Sensitivity Check Index (QUICKI)</title>
        <description>The Quantitative Insulin Sensitivity Check Index (QUICKI) score, measures insulin sensitivity which is the inverse of insulin resistance. QUICKI is derived using the inverse of the sum of the logarithms of the fasting insulin and fasting glucose: 1 / (log(fasting insulin mU/L) + log(fasting glucose mg/dL)).</description>
        <time_frame>Baseline (Day 1) and Week 12</time_frame>
        <population>The Pharmacodynamic Population included all subjects who received at least one dose of study medication and had PD biomarker data available, although only participants with both baseline and post-baseline data were included in the statistical analysis. Here, 'N' signifies number of participants analyzed for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: Placebo</title>
            <description>Placebo (Matching with BMS-986036) 0 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: BMS-986036 (1 mg Daily)</title>
            <description>BMS-986036 1 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: BMS-986036 (5 mg Daily)</title>
            <description>BMS-986036 5 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: BMS-986036 (20 mg Daily)</title>
            <description>BMS-986036 20 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Treatment E: BMS-986036 (20 mg Weekly)</title>
            <description>BMS-986036 20 mg subcutaneous injection once weekly (on Day 1 of each week) for 12 weeks followed by Placebo (Matching with BMS-986036) 0 mg subcutaneous injection on Days 2-7 of each week for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Insulin Sensitivity Quantified by Quantitative Insulin Sensitivity Check Index (QUICKI)</title>
          <description>The Quantitative Insulin Sensitivity Check Index (QUICKI) score, measures insulin sensitivity which is the inverse of insulin resistance. QUICKI is derived using the inverse of the sum of the logarithms of the fasting insulin and fasting glucose: 1 / (log(fasting insulin mU/L) + log(fasting glucose mg/dL)).</description>
          <population>The Pharmacodynamic Population included all subjects who received at least one dose of study medication and had PD biomarker data available, although only participants with both baseline and post-baseline data were included in the statistical analysis. Here, 'N' signifies number of participants analyzed for this outcome measure.</population>
          <units>Unit on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.011"/>
                    <measurement group_id="O2" value="0.00" spread="0.010"/>
                    <measurement group_id="O3" value="0.00" spread="0.015"/>
                    <measurement group_id="O4" value="0.00" spread="0.016"/>
                    <measurement group_id="O5" value="0.00" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Oral Glucose Tolerance Test (OGTT) Area Under the Curve From 0 to 2 Hours for Postprandial Glucose From Baseline to Week 12</title>
        <description>Blood samples were drawn after an overnight fast and standard OGTT from 0 to 120 minutes. Plasma Glucose levels over 2 hours were shown as Area Under the Curve, (AUC).</description>
        <time_frame>Baseline (Day 1) and Week 12</time_frame>
        <population>The Pharmacodynamic Population included all participants who received at least one dose of study medication and had PD biomarker data available, although only participants with both baseline and post-baseline data were included in the statistical analysis. Here, 'N' signifies number of participants analyzed for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: Placebo</title>
            <description>Placebo (Matching with BMS-986036) 0 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: BMS-986036 (1 mg Daily)</title>
            <description>BMS-986036 1 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: BMS-986036 (5 mg Daily)</title>
            <description>BMS-986036 5 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: BMS-986036 (20 mg Daily)</title>
            <description>BMS-986036 20 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Treatment E: BMS-986036 (20 mg Weekly)</title>
            <description>BMS-986036 20 mg subcutaneous injection once weekly (on Day 1 of each week) for 12 weeks followed by Placebo (Matching with BMS-986036) 0 mg subcutaneous injection on Days 2-7 of each week for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Oral Glucose Tolerance Test (OGTT) Area Under the Curve From 0 to 2 Hours for Postprandial Glucose From Baseline to Week 12</title>
          <description>Blood samples were drawn after an overnight fast and standard OGTT from 0 to 120 minutes. Plasma Glucose levels over 2 hours were shown as Area Under the Curve, (AUC).</description>
          <population>The Pharmacodynamic Population included all participants who received at least one dose of study medication and had PD biomarker data available, although only participants with both baseline and post-baseline data were included in the statistical analysis. Here, 'N' signifies number of participants analyzed for this outcome measure.</population>
          <units>Millimole*hour per Liter (mmol*hr/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.538" spread="4.2940"/>
                    <measurement group_id="O2" value="2.594" spread="5.8193"/>
                    <measurement group_id="O3" value="-0.646" spread="7.0591"/>
                    <measurement group_id="O4" value="-0.215" spread="4.7397"/>
                    <measurement group_id="O5" value="-2.293" spread="4.9322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in OGTT Insulin AUC (0-2 Hours) From Baseline to Week 12</title>
        <description>Blood samples were drawn after an overnight fast and standard OGTT from 0 to 120 minutes. Insulin levels over 2 hours were shown as Area Under the Curve, (AUC).</description>
        <time_frame>Bseline (Day 1) and Week 12</time_frame>
        <population>The Pharmacodynamic Population included all participants who received at least one dose of study medication and had PD biomarker data available, although only participants with both baseline and post-baseline data were included in the statistical analysis. Here, 'N' signifies number of participants analyzed for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: Placebo</title>
            <description>Placebo (Matching with BMS-986036) 0 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: BMS-986036 (1 mg Daily)</title>
            <description>BMS-986036 1 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: BMS-986036 (5 mg Daily)</title>
            <description>BMS-986036 5 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: BMS-986036 (20 mg Daily)</title>
            <description>BMS-986036 20 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Treatment E: BMS-986036 (20 mg Weekly)</title>
            <description>BMS-986036 20 mg subcutaneous injection once weekly (on Day 1 of each week) for 12 weeks followed by Placebo (Matching with BMS-986036) 0 mg subcutaneous injection on Days 2-7 of each week for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in OGTT Insulin AUC (0-2 Hours) From Baseline to Week 12</title>
          <description>Blood samples were drawn after an overnight fast and standard OGTT from 0 to 120 minutes. Insulin levels over 2 hours were shown as Area Under the Curve, (AUC).</description>
          <population>The Pharmacodynamic Population included all participants who received at least one dose of study medication and had PD biomarker data available, although only participants with both baseline and post-baseline data were included in the statistical analysis. Here, 'N' signifies number of participants analyzed for this outcome measure.</population>
          <units>mmol*hr/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-64.648" spread="231.6043"/>
                    <measurement group_id="O2" value="-72.155" spread="277.4819"/>
                    <measurement group_id="O3" value="-83.850" spread="215.3974"/>
                    <measurement group_id="O4" value="-58.313" spread="205.1879"/>
                    <measurement group_id="O5" value="-150.679" spread="257.5965"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in OGTT C-peptide AUC (0-2 Hours) From Baseline to Week 12</title>
        <description>Blood samples were drawn after an overnight fast and standard OGTT from 0 to 120 minutes. C-peptide levels over 2 hours were shown as Area Under the Curve, (AUC).</description>
        <time_frame>Baseline (Day 1) and Week 12</time_frame>
        <population>The Pharmacodynamic Population included all participants who received at least one dose of study medication and had PD biomarker data available, although only participants with both baseline and post-baseline data were included in the statistical analysis. Here, 'N' signifies number of participants analyzed for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: Placebo</title>
            <description>Placebo (Matching with BMS-986036) 0 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: BMS-986036 (1 mg Daily)</title>
            <description>BMS-986036 1 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: BMS-986036 (5 mg Daily)</title>
            <description>BMS-986036 5 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: BMS-986036 (20 mg Daily)</title>
            <description>BMS-986036 20 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Treatment E: BMS-986036 (20 mg Weekly)</title>
            <description>BMS-986036 20 mg subcutaneous injection once weekly (on Day 1 of each week) for 12 weeks followed by Placebo (Matching with BMS-986036) 0 mg subcutaneous injection on Days 2-7 of each week for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in OGTT C-peptide AUC (0-2 Hours) From Baseline to Week 12</title>
          <description>Blood samples were drawn after an overnight fast and standard OGTT from 0 to 120 minutes. C-peptide levels over 2 hours were shown as Area Under the Curve, (AUC).</description>
          <population>The Pharmacodynamic Population included all participants who received at least one dose of study medication and had PD biomarker data available, although only participants with both baseline and post-baseline data were included in the statistical analysis. Here, 'N' signifies number of participants analyzed for this outcome measure.</population>
          <units>mmol*hr/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.287" spread="1.2463"/>
                    <measurement group_id="O2" value="0.031" spread="1.3926"/>
                    <measurement group_id="O3" value="-0.181" spread="0.8927"/>
                    <measurement group_id="O4" value="-0.169" spread="1.0176"/>
                    <measurement group_id="O5" value="-0.750" spread="1.2224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Concentration (Cavg) of C-terminal Intact BMS-986036</title>
        <description>Cavg of C-terminal Intact BMS-986036 was reported.</description>
        <time_frame>Pre-dose, 6, 24 hours postdose on Week 8; pre-dose on Weeks 1, 2, 4, 6, 8, and 12; post treatment period on Week 13, 15 and 18 (Day 126)</time_frame>
        <population>Serum concentration-time data will be used to develop a population PK model, and estimates of individual PK parameters will be derived from this model using a validated PK analysis program. Here, 'N' signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment B: BMS-986036 (1 mg Daily)</title>
            <description>BMS-986036 1 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment C: BMS-986036 (5 mg Daily)</title>
            <description>BMS-986036 5 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Treatment D: BMS-986036 (20 mg Daily)</title>
            <description>BMS-986036 20 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Treatment E: BMS-986036 (20 mg Weekly)</title>
            <description>BMS-986036 20 mg subcutaneous injection once weekly (on Day 1 of each week) for 12 weeks followed by Placebo (Matching with BMS-986036) 0 mg subcutaneous injection on Days 2-7 of each week for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Concentration (Cavg) of C-terminal Intact BMS-986036</title>
          <description>Cavg of C-terminal Intact BMS-986036 was reported.</description>
          <population>Serum concentration-time data will be used to develop a population PK model, and estimates of individual PK parameters will be derived from this model using a validated PK analysis program. Here, 'N' signifies number of participants evaluable for this outcome measure.</population>
          <units>Microgram per Liter (ug/L)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.6" spread="60.6"/>
                    <measurement group_id="O2" value="204" spread="50.4"/>
                    <measurement group_id="O3" value="762" spread="49.2"/>
                    <measurement group_id="O4" value="197" spread="60.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Concentration (Cmax) of C-terminal Intact BMS-986036</title>
        <description>Maximum observed concentration (Cmax) of C-terminal Intact BMS-986036 was reported.</description>
        <time_frame>Pre-dose, 6, 24 hours postdose on Week 8; pre-dose on Weeks 1, 2, 4, 6, 8, and 12; post treatment period on Week 13, 15 and 18 (Day 126)</time_frame>
        <population>Serum concentration-time data will be used to develop a population PK model, and estimates of individual PK parameters will be derived from this model using a validated PK analysis program. Here, 'N' signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment B: BMS-986036 (1 mg Daily)</title>
            <description>BMS-986036 1 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment C: BMS-986036 (5 mg Daily)</title>
            <description>BMS-986036 5 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Treatment D: BMS-986036 (20 mg Daily)</title>
            <description>BMS-986036 20 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Treatment E: BMS-986036 (20 mg Weekly)</title>
            <description>BMS-986036 20 mg subcutaneous injection once weekly (on Day 1 of each week) for 12 weeks followed by Placebo (Matching with BMS-986036) 0 mg subcutaneous injection on Days 2-7 of each week for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Concentration (Cmax) of C-terminal Intact BMS-986036</title>
          <description>Maximum observed concentration (Cmax) of C-terminal Intact BMS-986036 was reported.</description>
          <population>Serum concentration-time data will be used to develop a population PK model, and estimates of individual PK parameters will be derived from this model using a validated PK analysis program. Here, 'N' signifies number of participants evaluable for this outcome measure.</population>
          <units>microgram/liter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.3" spread="61.2"/>
                    <measurement group_id="O2" value="213" spread="50.4"/>
                    <measurement group_id="O3" value="807" spread="48.8"/>
                    <measurement group_id="O4" value="459" spread="41.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve From Time Zero to 24 Hours at Steady State (AUC [0-24 Hours, ss]) of C-terminal Intact BMS-986036</title>
        <description>AUC [0-24 hours, ss] of C-terminal Intact BMS-986036 was reported.</description>
        <time_frame>Pre-dose, 6, 24 hours postdose on Week 8</time_frame>
        <population>Serum concentration-time data will be used to develop a population PK model, and estimates of individual PK parameters will be derived from this model using a validated PK analysis program. Here, 'N' signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment B: BMS-986036 (1 mg Daily)</title>
            <description>BMS-986036 1 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment C: BMS-986036 (5 mg Daily)</title>
            <description>BMS-986036 5 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Treatment D: BMS-986036 (20 mg Daily)</title>
            <description>BMS-986036 20 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Treatment E: BMS-986036 (20 mg Weekly)</title>
            <description>BMS-986036 20 mg subcutaneous injection once weekly (on Day 1 of each week) for 12 weeks followed by Placebo (Matching with BMS-986036) 0 mg subcutaneous injection on Days 2-7 of each week for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time Zero to 24 Hours at Steady State (AUC [0-24 Hours, ss]) of C-terminal Intact BMS-986036</title>
          <description>AUC [0-24 hours, ss] of C-terminal Intact BMS-986036 was reported.</description>
          <population>Serum concentration-time data will be used to develop a population PK model, and estimates of individual PK parameters will be derived from this model using a validated PK analysis program. Here, 'N' signifies number of participants evaluable for this outcome measure.</population>
          <units>hour*microgram/liter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1210" spread="60.6"/>
                    <measurement group_id="O2" value="4900" spread="50.4"/>
                    <measurement group_id="O3" value="18300" spread="49.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve From Time Zero to 168 Hours at Steady State (AUC [0-168 Hours, ss]) of C-terminal Intact BMS-986036</title>
        <description>AUC [0-168 hours, ss] of C-terminal Intact BMS-986036 was reported.</description>
        <time_frame>Pre-dose, 6, 24 hours postdose on Week 8; pre-dose on Weeks 1, 2, 4, 6, 8, and 12; post treatment period on Week 13, 15 and 18 (Day 126)</time_frame>
        <population>Serum concentration-time data will be used to develop a population PK model, and estimates of individual PK parameters will be derived from this model using a validated PK analysis program. Here, 'N' signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment B: BMS-986036 (1 mg Daily)</title>
            <description>BMS-986036 1 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment C: BMS-986036 (5 mg Daily)</title>
            <description>BMS-986036 5 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Treatment D: BMS-986036 (20 mg Daily)</title>
            <description>BMS-986036 20 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Treatment E: BMS-986036 (20 mg Weekly)</title>
            <description>BMS-986036 20 mg subcutaneous injection once weekly (on Day 1 of each week) for 12 weeks followed by Placebo (Matching with BMS-986036) 0 mg subcutaneous injection on Days 2-7 of each week for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time Zero to 168 Hours at Steady State (AUC [0-168 Hours, ss]) of C-terminal Intact BMS-986036</title>
          <description>AUC [0-168 hours, ss] of C-terminal Intact BMS-986036 was reported.</description>
          <population>Serum concentration-time data will be used to develop a population PK model, and estimates of individual PK parameters will be derived from this model using a validated PK analysis program. Here, 'N' signifies number of participants evaluable for this outcome measure.</population>
          <units>hour*microgram/liter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="31800" spread="57.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Concentration (Cavg) of Total BMS-986036</title>
        <description>Cavg of Total BMS-986036 was reported.</description>
        <time_frame>Pre-dose, 6, 24 hours postdose on Week 8; pre-dose on Weeks 1, 2, 4, 6, 8, and 12; post treatment period on Week 13, 15 and 18 (Day 126)</time_frame>
        <population>Serum concentration-time data will be used to develop a population PK model, and estimates of individual PK parameters will be derived from this model using a validated PK analysis program. Here, 'N' signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment B: BMS-986036 (1 mg Daily)</title>
            <description>BMS-986036 1 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment C: BMS-986036 (5 mg Daily)</title>
            <description>BMS-986036 5 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Treatment D: BMS-986036 (20 mg Daily)</title>
            <description>BMS-986036 20 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Treatment E: BMS-986036 (20 mg Weekly)</title>
            <description>BMS-986036 20 mg subcutaneous injection once weekly (on Day 1 of each week) for 12 weeks followed by Placebo (Matching with BMS-986036) 0 mg subcutaneous injection on Days 2-7 of each week for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Concentration (Cavg) of Total BMS-986036</title>
          <description>Cavg of Total BMS-986036 was reported.</description>
          <population>Serum concentration-time data will be used to develop a population PK model, and estimates of individual PK parameters will be derived from this model using a validated PK analysis program. Here, 'N' signifies number of participants evaluable for this outcome measure.</population>
          <units>Microgram per Liter (ug/L)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="342" spread="42.3"/>
                    <measurement group_id="O2" value="1560" spread="44.6"/>
                    <measurement group_id="O3" value="6390" spread="43.2"/>
                    <measurement group_id="O4" value="1130" spread="38.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Concentration (Cmax) of Total BMS-986036</title>
        <description>Maximum observed concentration (Cmax) of Total BMS-986036 was reported.</description>
        <time_frame>Pre-dose, 6, 24 hours postdose on Week 8; pre-dose on Weeks 1, 2, 4, 6, 8, and 12; post treatment period on Week 13, 15 and 18 (Day 126)</time_frame>
        <population>Serum concentration-time data will be used to develop a population PK model, and estimates of individual PK parameters will be derived from this model using a validated PK analysis program. Here, 'N' signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment B: BMS-986036 (1 mg Daily)</title>
            <description>BMS-986036 1 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment C: BMS-986036 (5 mg Daily)</title>
            <description>BMS-986036 5 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Treatment D: BMS-986036 (20 mg Daily)</title>
            <description>BMS-986036 20 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Treatment E: BMS-986036 (20 mg Weekly)</title>
            <description>BMS-986036 20 mg subcutaneous injection once weekly (on Day 1 of each week) for 12 weeks followed by Placebo (Matching with BMS-986036) 0 mg subcutaneous injection on Days 2-7 of each week for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Concentration (Cmax) of Total BMS-986036</title>
          <description>Maximum observed concentration (Cmax) of Total BMS-986036 was reported.</description>
          <population>Serum concentration-time data will be used to develop a population PK model, and estimates of individual PK parameters will be derived from this model using a validated PK analysis program. Here, 'N' signifies number of participants evaluable for this outcome measure.</population>
          <units>microgram/liter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="344" spread="42.5"/>
                    <measurement group_id="O2" value="1570" spread="44.5"/>
                    <measurement group_id="O3" value="6440" spread="43.1"/>
                    <measurement group_id="O4" value="1420" spread="36.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve From Time Zero to 24 Hours at Steady State (AUC [0-24 Hours, ss]) Total BMS-986036</title>
        <description>AUC [0-24 hours, ss] of Total BMS-986036 was reported.</description>
        <time_frame>Pre-dose, 6, 24 hours postdose on Week 8</time_frame>
        <population>Serum concentration-time data will be used to develop a population PK model, and estimates of individual PK parameters will be derived from this model using a validated PK analysis program. Here, 'N' signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment B: BMS-986036 (1 mg Daily)</title>
            <description>BMS-986036 1 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment C: BMS-986036 (5 mg Daily)</title>
            <description>BMS-986036 5 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Treatment D: BMS-986036 (20 mg Daily)</title>
            <description>BMS-986036 20 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Treatment E: BMS-986036 (20 mg Weekly)</title>
            <description>BMS-986036 20 mg subcutaneous injection once weekly (on Day 1 of each week) for 12 weeks followed by Placebo (Matching with BMS-986036) 0 mg subcutaneous injection on Days 2-7 of each week for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time Zero to 24 Hours at Steady State (AUC [0-24 Hours, ss]) Total BMS-986036</title>
          <description>AUC [0-24 hours, ss] of Total BMS-986036 was reported.</description>
          <population>Serum concentration-time data will be used to develop a population PK model, and estimates of individual PK parameters will be derived from this model using a validated PK analysis program. Here, 'N' signifies number of participants evaluable for this outcome measure.</population>
          <units>hour*microgram/liter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8200" spread="42.3"/>
                    <measurement group_id="O2" value="37400" spread="44.6"/>
                    <measurement group_id="O3" value="153000" spread="43.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve From Time Zero to 168 Hours at Steady State (AUC [0-168 Hours, ss]) of Total BMS-986036</title>
        <description>AUC [0-168 hours, ss] of Total BMS- 986036 was reported.</description>
        <time_frame>Pre-dose, 6, 24 hours postdose on Week 8; pre-dose on Weeks 1, 2, 4, 6, 8, and 12; post treatment period on Week 13, 15 and 18 (Day 126)</time_frame>
        <population>Serum concentration-time data will be used to develop a population PK model, and estimates of individual PK parameters will be derived from this model using a validated PK analysis program. Here, 'N' signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment B: BMS-986036 (1 mg Daily)</title>
            <description>BMS-986036 1 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment C: BMS-986036 (5 mg Daily)</title>
            <description>BMS-986036 5 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Treatment D: BMS-986036 (20 mg Daily)</title>
            <description>BMS-986036 20 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Treatment E: BMS-986036 (20 mg Weekly)</title>
            <description>BMS-986036 20 mg subcutaneous injection once weekly (on Day 1 of each week) for 12 weeks followed by Placebo (Matching with BMS-986036) 0 mg subcutaneous injection on Days 2-7 of each week for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time Zero to 168 Hours at Steady State (AUC [0-168 Hours, ss]) of Total BMS-986036</title>
          <description>AUC [0-168 hours, ss] of Total BMS- 986036 was reported.</description>
          <population>Serum concentration-time data will be used to develop a population PK model, and estimates of individual PK parameters will be derived from this model using a validated PK analysis program. Here, 'N' signifies number of participants evaluable for this outcome measure.</population>
          <units>hour*microgram/liter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="172000" spread="39.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With ANTI-BMS-986036 Antibody Response</title>
        <description>Percentage of Participants with ANTI-BMS-986036 Antibody Response (ADA positive and ADA Negative) was reported. Participants were monitored for antibodies to BMS-986036 with an anti-BMS-986036 antibody assay. Titers were reported for samples testing positive in an assay.</description>
        <time_frame>Baseline and Day 126</time_frame>
        <population>It included all treated participants who were randomized to treatment and subsequently received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment B: BMS-986036 (1 mg Daily)</title>
            <description>BMS-986036 1 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment C: BMS-986036 (5 mg Daily)</title>
            <description>BMS-986036 5 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Treatment D: BMS-986036 (20 mg Daily)</title>
            <description>BMS-986036 20 mg subcutaneous injection once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Treatment E: BMS-986036 (20 mg Weekly)</title>
            <description>BMS-986036 20 mg subcutaneous injection once weekly (on Day 1 of each week) for 12 weeks followed by Placebo (Matching with BMS-986036) 0 mg subcutaneous injection on Days 2-7 of each week for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With ANTI-BMS-986036 Antibody Response</title>
          <description>Percentage of Participants with ANTI-BMS-986036 Antibody Response (ADA positive and ADA Negative) was reported. Participants were monitored for antibodies to BMS-986036 with an anti-BMS-986036 antibody assay. Titers were reported for samples testing positive in an assay.</description>
          <population>It included all treated participants who were randomized to treatment and subsequently received at least one dose of study medication.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ADA Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5"/>
                    <measurement group_id="O2" value="79.2"/>
                    <measurement group_id="O3" value="83.3"/>
                    <measurement group_id="O4" value="58.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADA Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="12.5"/>
                    <measurement group_id="O4" value="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Approximately 2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment A: Placebo</title>
          <description>Placebo (Matching with BMS-986036) 0 mg subcutaneous injection once daily for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Treatment B: BMS-986036 (1 mg Daily)</title>
          <description>BMS-986036 1 mg subcutaneous injection once daily for 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Treatment C: BMS-986036 (5 mg Daily)</title>
          <description>BMS-986036 5 mg subcutaneous injection once daily for 12 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Treatment D: BMS-986036 (20 mg Daily)</title>
          <description>BMS-986036 20 mg subcutaneous injection once daily for 12 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Treatment E: BMS-986036 (20 mg Weekly)</title>
          <description>BMS-986036 20 mg subcutaneous injection once weekly (on Day 1 of each week) for 12 weeks followed by Placebo (Matching with BMS-986036) 0 mg subcutaneous injection on Days 2-7 of each week for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Mitral Valve Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Tricuspid Valve Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Bruising</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hunger</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Creatine Phosphokinase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Increased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Bristol-Myers Squibb</organization>
      <email>clinical.trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

